SpringWorks Therapeutics reported fourth quarter 2024 OGSIVEO U.S. net product revenues of $61.5 million, contributing to a full year 2024 total of $172.0 million. These figures demonstrate robust commercial execution for its first approved therapy.
The company ended 2024 with a solid cash position, reporting $461.9 million in cash, cash equivalents, and marketable securities. This financial strength supports ongoing operations and future commercialization efforts.
A key business update included the recent FDA approval of GOMEKLI (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amenable to complete resection. This approval marks the addition of a second commercial product to SpringWorks' portfolio and sets the stage for global expansion, with initial OGSIVEO launches in the European Union planned for mid-2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.